drugset / Trial / NCT03920631
Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to find out if microtransplantation (MST) in combination with nivolumab is safe and effective in patients with relapsed or refractory B cell lymphomas.
Timeline
- Start
- 2020-07-10
- Primary completion
- 2023-03-15
- Completion
- 2023-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Microtransplantation | Cell therapy | — | — |
| Subject | Nivolumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | — |